CA2530159A1 - N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors - Google Patents

N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors Download PDF

Info

Publication number
CA2530159A1
CA2530159A1 CA002530159A CA2530159A CA2530159A1 CA 2530159 A1 CA2530159 A1 CA 2530159A1 CA 002530159 A CA002530159 A CA 002530159A CA 2530159 A CA2530159 A CA 2530159A CA 2530159 A1 CA2530159 A1 CA 2530159A1
Authority
CA
Canada
Prior art keywords
pyrrolidin
benzamide
dichloro
isobutyl
4alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002530159A
Other languages
French (fr)
Other versions
CA2530159C (en
Inventor
Paul Vincent Fish
Michael Jonathan Fray
Alan Stobie
Florian Wakenhut
Gavin Alistair Whitlock
Mark David Andrews
Alan Daniel Brown
Mark Ian Lansdell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc.
Paul Vincent Fish
Michael Jonathan Fray
Alan Stobie
Florian Wakenhut
Gavin Alistair Whitlock
Mark David Andrews
Alan Daniel Brown
Mark Ian Lansdell
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0314048.0A external-priority patent/GB0314048D0/en
Application filed by Pfizer Inc., Paul Vincent Fish, Michael Jonathan Fray, Alan Stobie, Florian Wakenhut, Gavin Alistair Whitlock, Mark David Andrews, Alan Daniel Brown, Mark Ian Lansdell, Pfizer Limited filed Critical Pfizer Inc.
Publication of CA2530159A1 publication Critical patent/CA2530159A1/en
Application granted granted Critical
Publication of CA2530159C publication Critical patent/CA2530159C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein R1 is H, C1_6alkyl, -C(X)Y, C3_8cycloalkyl, aryl, het, aryl-Cl_4alkyl or het-Cl_4alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted by at least one substituent independently selected from C1_8allkyl, C1_8alkoxy, OH, halo, CF3, OCF3, SCF3, hydroxy-Cl_6alkyl, C1_ 4alkoxy-C1_6alkyl and C1_4alkyl-S-C1_4alkyl; R2 is aryl or heteroaryl, each optionally substituted by at least one substituent independently selected from C1_8alkyl, C1_8alkoxy, OH, halo, CF3, OCF3, SCF3, hydroxy-C1_6alkyl, C1_4alkoxy-C1_6alkyl and C1_4alkyl-S-C1_4alkyl; R3 is C1_6alkyl, C3_8cycloalkyl, C3_8cycloalkyl-C1_6alkyl, aryl, het, aryl-Cl_4alkyl or het-C1_4alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted by at least one substituent independently selected from C1_6alkyl, C1_6alkoxy, OH, halo, CF3, OCF3, SCF3, hydroxy-C1_6alkyl, C1_4alkoxy -C1_6alkyl and C1_4alkyl-S~C1_4alkyl; X is S or O; Y is H, C1_6alkyl, aryl, het, aryl-C1_4alkyl or het-C1_ 4alkyl; and n is 1 or 2, provided that when n is 1, m is 0 or 1 and when n is 2, m is 0, wherein if m is 0, then *
represents a chiral center. The compounds of the invention exhibit activity as both serotonin and noradrenaline re-uptake inhibitors and therefore have utility in a variety of therapeutic areas, for example urinary incontinence.

Claims (24)

1. A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein R1 is H, C1-6alkyl, -C(X)Y, C3-8cycloalkyl, aryl, het, aryl-C1-4alkyl or het-C1-4alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted by at least one substituent independently selected from C1-8allkyl, C1-8alkoxy, OH, halo, CF3, OCF3, SCF3, hydroxy-C1-8alkyl, C1-4alkoxy-C1-8alkyl and C1-4alkyl-S-C1-4alkyl;
R2 is aryl or heteroaryl, each optionally substituted by at least one substituent independently selected from C1-8alkyl, C1-8alkoxy, OH, halo, CF3, OCF3, SCF3, hydroxy-C1-6alkyl, C1-4alkoxy-C1-6alkyl and C1-4alkyl-S-C1-4alkyl;
R3 is C1-6alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-6alkyl, aryl, het, aryl-C1-4alkyl or het-C1-4alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted by at least one substituent independently selected from C1-6alkyl, C1-6alkoxy, OH, halo, CF3, OCF3, SCF3, hydroxy-C1-6alkyl, C1-4alkoxy - C1-6alkyl and C1-4alkyl-S-C1-4alkyl;
X is S or O;
Y is H, C1-6alkyl, aryl, het, aryl-C1-4alkyl or het-C1-4alkyl;
n is 1 or 2, provided that when n is 1, m is 0 or 1 and when n is 2, m is 0, wherein if m is 0, then * represents a chiral centre;
aryl is phenyl, naphthyl, anthracyl or phenanthryl;

heteroaryl is an aromatic 5- or 6- membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to an aryl group;
het is an aromatic or non-aromatic 4-, 5- or 6- membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 5-or 6- membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom.
2. A compound according to Claim 1, wherein R1 is H.
3. A compound according to Claim 1 or Claim 2, wherein m is 0 and represents the R or S enantiomer.
4. A compound according to Claim 3, wherein * represents the S
enantiomer.
5. A compound according to any preceding claim, wherein R2 is phenyl, naphthyl or quinolinyl, each optionally substituted by at least one substituent independently selected from C1-8alkyl, C1-8alkoxy, OH, halo, CF3, OCF3, SCF3, hydroxy-C1-6alkyl, C1-4alkoxy-C1-6alkyl and C1-4alkyl-S-C1-4alkyl.
6. A compound according to Claim 5, wherein R2 is phenyl or naphthyl each optionally substituted by one, two or three substituents independently selected from halo, OH, C1-4alkyl and CF3.
7. A compound according to any preceding claim, wherein R3 is C1-6alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-4alkyl or aryl-C1-4alkyl.
8. A compound according to Claim 7, wherein R3 is C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-2alkyl, phenyl-CH2- or naphthyl-Ch2-.
9. A compound according to Claim 1, wherein R1 is H;

R2 is phenyl or naphthyl each optionally substituted by one, two or three substituents independently selected from halo, OH, C1-4alkyl and CF3;
R3 is C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-3alkyl, phenyl-CH2- or naphthyl-CH2-; and m is 0.
10. A compound according to Claim 1, selected from:
2,3-Dichloro-N-isobutyl-N-[(3S)-pyrrolidin-3-yl]benzamide;
2,4-Dichloro-N-isobutyl-N-[(3S)-pyrrolidin-3-yl]benzamide;
2-Chloro-3-methyl-N-isobutyl-N-[(3S)-pyrrolidin-3-yl]benzamide;
3-Fluoro-2-methyl-N isobutyl-N-[(3S)-pyrrolidin-3-yl]benzamide;
3-Methoxy-2-methyl-N-isobutyl-N-[(3S)-pyrrolidin-3-yl]benzamide;
3-Chloro-N-isobutyl-N-[(3S)-pyrrolidin-3-yl]benzamide;
4-Chloro-N-isobutyl-N-[(3S)-pyrrolidin-3-yl]benzamide;
3,4-Dichloro-N-isobutyl-N-[(3S)-pyrrolidin-3-yl]benzamide;
N-(2-Naphthylmethyl)-N-[(3S)-pyrrolidin-3-yl]benzamide;
N-(2-Naphthylmethyl)-N-[(3R)-pyrrolidin-3-yl]benzamide;
N-Isobutyl-N-[(3S)-pyrrolidin-3-yl]-2-naphthamide;
N-Butyl-N-[(3S)-pyrrolidin-3-yl]-1-naphthamide;
4-Chloro-N-(3,4-dichlorobenzyl)-N-[(3R)-pyrrolidin-3-yl]benzamide;
N-Pyrrolidin-3-yl-N-(5,6,7,8-tetrahydro-naphthalen-1-ylmethyl)-benzamide;
N-(2,4-Dichloro-benzyl)-N-pyrrolidin-3-yl-benzamide;
N-(3-Chloro-4-methyl-benzyl)-2-fluoro-N-pyrrolidin-3-yl-benzamide;
Naphthalene-2-carboxylic acid butyl-pyrrolidin-3-yl-amide;
Naphthalene-2-carboxylic acid isobutyl-pyrrolidin-3-yl-amide;
Naphthalene-2-carboxylic acid (2,2-dimethyl-propyl)-pyrrolidin-3-yl-amide;
3-Chloro-N-isobutyl-4-methyl-N-pyrrolidin-3-yl-benzamide;
N-Isobutyl-2,3-dimethyl-N-pyrrolidin-3-yl-benzamide;
3-Chloro-N-(2,2-dimethyl-propyl)-2-methyl-N-pyrrolidin-3-yl-benzamide;
2-Chloro-4-fluoro-N-isobutyl-N-pyrrolidin-3-yl-benzamide;
2-Chloro-N-isobutyl-N-pyrrolidin-3-yl-benzamide;
3-Chloro-2-fluoro-N-isobutyl-N-pyrrolidin-3-yl-benzamide;
3-Chloro-4-fluoro-N-isobutyl-N-pyrrolidin-3-yl-benzamide;

N-Butyl-2,4-dichloro-N-pyrrolidin-3-yl-benzamide;
2,4-Dichloro-N-cyclobutylmethyl-N-pyrrolidin-3-yl-benzamide;
2,4-Dichloro-N-cyclopentylmethyl-N-pyrrolidin-3-yl-benzamide;
2,4-Dichloro-N-(2,2-dimethyl-propyl)-2-methyl-N-pyrrolidin-3-yl-benzamide;
2,4-Dichloro-N-(2-ethyl-butyl)-N-pyrrolidin-3-yl-benzamide;
2,4-Dichloro-N-(3-methyl-butyl)-N-pyrrolidin-3-yl-benzamide;
2,3,4-Trichloro-N-isobutyl-N-pyrrolidin-3-yl-benzamide;
2,4-Dichloro-N-(2-cyclopropyl-ethyl)-N-pyrrolidin-3-yl-benzamide;
Naphthalene-1-carboxylic acid isobutyl-pyrrolidin-3-yl-amide;
2,4-Dichloro-5-fluoro-N-isobutyl-N-pyrrolidin-3-yl-benzamide;
2,3-Dichloro-N-(2,2-dimethyl-propyl)-N-pyrrolidin-3-yl-benzamide;
2,3-Dichloro-N-(3-methyl-butyl)-N-pyrrolidin-3-yl-benzamide;
2,3-Dichloro-N-cyclobutylmethyl-N-pyrrolidin-3-yl-benzamide;
2,3-Dichloro-N-cyclopentyl-N-pyrrolidin-3-yl-benzamide;
3,4-Dichloro-N-cyclopentyl-N-pyrrolidin-3-yl-benzamide;
2,3-Dichloro-N-(1,2-dimethyl-propyl)-N-pyrrolidin-3-yl-benzamide;
2,4-Dichloro-N-(1,2-dimethyl-propyl)-N-pyrrolidin-3-yl-benzamide;
2,3-Dichloro-N-cyclohexyl-N-pyrrolidin-3-yl-benzamide;
2,4-Dichloro-N-cyclopentyl-N-pyrrolidin-3-yl-benzamide;
3,4-Dichloro-N-cyclopentyl-N-pyrrolidin-3-yl-benzamide;
Naphthalene-1-carboxylic acid sec-butyl-pyrrolidin-3-yl-amide;
N-sec-Butyl-2,3-dichloro-N-pyrrolidin-3-yl-benzamide;
N-sec-Butyl-2,4-dichloro-N-pyrrolidin-3-yl-benzamide;
2,3-Dichloro-N-(1-ethyl-propyl)-N-pyrrolidin-3-yl-benzamide;
2,4-Dichloro-N-(1-ethyl-propyl)-N-pyrrolidin-3-yl-benzamide;
Naphthalene-1-carboxylic acid (1-ethyl-propyl)-pyrrolidin-3-yl-amide;
2,3-Dichloro-N-cyclobutyl-N-pyrrolidin-3-yl-benzamide;
2,4-Dichloro-N-cyclobutyl-N-pyrrolidin-3-yl-benzamide;
2,4-Dichloro-N-cyclopentyl-N-pyrrolidin-3-yl-benzamide;
2,3-Dichloro-N-pyrrolidin-3-yl-N-(1,2,2-trimethyl-propyl)-benzamide;
N-tert-Butyl-2,3-dichloro-N-pyrrolidin-3-yl-benzamide;
Naphthalene-1-carboxylic acid cyclopentyl-pyrrolidin-3-yl-amide;
2,3-Dichloro-N-phenyl-N-pyrrolidin-3-yl-benzamide;

3,4-Dichloro-N-(2,2-dimethyl-propyl)-2-methyl-N-pyrrolidin-3-yl-benzamide;
3-Chloro-N-isobutyl-2-methyl-N-pyrrolidin-3-yl-benzamide;
N-Butyl-2,3-dichloro-N-pyrrolidin-3-yl-benzamide;
N-Butyl-3,4-dichloro-N-pyrrolidin-3-yl-benzamide;
Naphthalene-2-carboxylic acid cyclobutylmethyl-pyrrolidin-3-yl-amide;
Naphthalene-1-carboxylic acid cyclobutylmethyl-pyrrolidin-3-yl-amide;
3,4-Dichloro-N-cyclobutylmethyl-N-pyrrolidin-3-yl-benzamide;
4-Chloro-N-isobutyl-2-methoxy-N-pyrrolidin-3-yl-benzamide;
4-Chloro-N-isobutyl-3-methyl-N-pyrrolidin-3-yl-benzamide;
2,4-Dichloro-N-isobutyl-3-methyl-N-pyrrolidin-3-yl-benzamide;
Naphthalene-1-carboxylic acid (3-methyl-butyl)-pyrrolidin-3-yl-amide;
Naphthalene-1-carboxylic acid (2,2-dimethyl-propyl)-pyrrolidin-3-yl-amide;
3,4-Dichloro-N-(3-methyl-butyl)-N-pyrrolidin-3-yl-benzamide;
2,3-Dichloro-N-(4-fluoro-phenyl)-N-pyrrolidin-3-yl-benzamide;
2,4-Dichloro-N-(4-fluoro-phenyl)-N-pyrrolidin-3-yl-benzamide;
Naphthalene-1-carboxylic acid (4-fluoro-phenyl)-pyrrolidin-3-yl-amide;
N-Butyl-2,3,4-trichloro-N-pyrrolidin-3-yl-benzamide;
2,3,4-Trichloro-N-cyclobutylmethyl-N-pyrrolidin-3-yl-benzamide;
N-Pyrrolidin-3-yl-N-(3-trifluoromethyl-benzyl)-benzamide;
2,4-Dichloro-N-phenyl-N-pyrrolidin-3-yl-benzamide;
3,4-Dichloro-N-phenyl-N-pyrrolidin-3-yl-benzamide;
2,3,4-Trichloro-N-(2,2-dimethyl-propyl)-N-pyrrolidin-3-yl-benzamide;
Naphthalene-1-carboxylic acid phenyl-pyrrolidin-3-yl-amide;
2,3,4-Trichloro-N-(2-cyclopropyl-ethyl)-N-pyrrolidin-3-yl-benzamide;
2,3-Dichloro-N-(2-cyclopropyl-ethyl)-N-pyrrolidin-3-yl-benzamide;
2-Bromo-4-chloro-N-isobutyl-N-pyrrolidin-3-yl-benzamide;
4-Chloro-2-ethoxy-N-isobutyl-N-pyrrolidin-3-yl-benzamide;
3-Bromo-4-chloro-N-isobutyl-N-pyrrolidin-3-yl-benzamide;
2,4-Dichloro-5-fluoro-N isobutyl-N [(3S)-pyrrolidin-3-yl]benzamide;
3,4-Dichloro-N-isobutyl-2-methyl-N-pyrrolidin-3-yl-benzamide;
2,4-dichloro-3-fluoro-N isobutyl-N [pyrrolidin-3-yl]benzamide;
2,3-dichloro-4-fluoro-N isobutyl-N-[pyrrolidin-3-yl]benzamide;
2,3-dichloro-5-fluoro-N isobutyl-N [pyrrolidin-3-yl]benzamide;

2,4,5-trichloro-N-isobutyl-N-[pyrrolidin-3-yl]benzamide;
2,5-dichloro-N-isobutyl-N-[pyrrolidin-3-yl]benzamide;
2,5-dichloro-4-fluoro-N-isobutyl-N-[pyrrolidin-3-yl]benzamide;
2,3,5-trichloro-N-isobutyl-N-[pyrrolidin-3-yl]benzamide;
2,3-dichloro-6-fluoro-N-isobutyl-N-[pyrrolidin-3-yl]benzamide;
3,4,-dichloro-6-fluoro-N-isobutyl-N-[pyrrolidin-3-yl]benzamide;
3,4-dichloro-2-fluoro-N-isobutyl-N-[pyrrolidin-3-yl]benzamide;
2-chloro-3,6-difluoro-N-isobutyl-N-[pyrrolidin-3-yl]benzamide; and 4-Chloro-N-(2,3-dichlorobenzyl)-N-[(3R)-pyrrolidin-3-yl]benzamide, or pharmaceutically and/or veterinarily acceptable derivatives thereof.
11. A compound according to Claim 10 which is 2,3-Dichloro-N-isobutyl-N-[(3S)-pyrrolidin-3-yl]benzamide or pharmaceutically and/or veterinarily acceptable derivatives thereof.
12. A pharmaceutical composition comprising a compound as claimed in any one of Claims 1 to 11 and a pharmaceutically acceptable adjuvant, diluent or carrier.
13. A compound according to any one of Claims 1-11 for use as a medicament.
14. Use of a compound according to any one of Claims 1-11 in the manufacture of a medicament for the treatment of a disorder in which the regulation of monoamine transporter function in mammals is implicated.
15. Use of a compound according to any one of Claims 1-11 in the manufacture of a medicament for the treatment of a disorder in which the regulation of serotonin or noradrenaline in mammals is implicated.
16. Use according to Claim 15, wherein the regulation of serotonin and noradrenaline is implicated.
17. Use of a compound according to any one of Claims 1-11 in the manufacture of a medicament for the treatment of urinary disorders, depression, pain, premature ejaculation, ADHD or fibromyalgia in mammals.
18. Use of a compound according to Claim 17, for the treatment of urinary incontinence, such as GSI or USI, in mammals.
19. A method of treatment of a disorder in which the regulation of monoamine transporter function is implicated which comprises administering a therapeutically effective amount of a compound according to any one of Claims 1-11 to a patient in need of such treatment.
20. A method of treatment of a disorder in which the regulation of serotonin or noradrenaline is implicated which comprises administering a therapeutically effective amount of a compound according to any one of Claims 1-11 to a patient in need of such treatment.
21. A method according to Claim 20, wherein the regulation of serotonin and noradrenaline is implicated.
22. A method of treatment of urinary disorders, depression, pain, premature ejaculation, ADHD or fibromyalgia, which comprises administering a therapeutically effective amount of a compound according to any one of Claims 1-11 to a patient in need of such treatment.
23. A method according to Claim 22, wherein the urinary disorder is urinary incontinence, such as GSI or USI.
24. A process for preparing a compound according to any one of Claims 1-11 comprising reacting a compound of formula (X):

wherein R3, n and m are as defined above and Y is R1 or a protecting group, with an acid or acyl halide: R2COX, wherein X is OH or halo, and deprotecting if necessary or desired.
CA002530159A 2003-06-17 2004-06-07 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors Expired - Fee Related CA2530159C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0314048.0A GB0314048D0 (en) 2003-06-17 2003-06-17 Novel compounds
GBGB0314048.0 2003-06-17
US49312603P 2003-08-06 2003-08-06
US60/493,126 2003-08-06
PCT/IB2004/001943 WO2004110995A1 (en) 2003-06-17 2004-06-07 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors

Publications (2)

Publication Number Publication Date
CA2530159A1 true CA2530159A1 (en) 2004-12-23
CA2530159C CA2530159C (en) 2010-02-02

Family

ID=33554153

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002530159A Expired - Fee Related CA2530159C (en) 2003-06-17 2004-06-07 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors

Country Status (31)

Country Link
US (2) US7378436B2 (en)
EP (1) EP1638933B1 (en)
JP (1) JP4137159B2 (en)
KR (1) KR100803796B1 (en)
AP (1) AP2005003467A0 (en)
AR (1) AR044715A1 (en)
AT (1) ATE398107T1 (en)
AU (1) AU2004247487B2 (en)
BR (1) BRPI0411594A (en)
CA (1) CA2530159C (en)
CY (1) CY1110434T1 (en)
DE (1) DE602004014372D1 (en)
DK (1) DK1638933T3 (en)
EA (1) EA009881B1 (en)
EC (1) ECSP056232A (en)
ES (1) ES2305776T3 (en)
HR (2) HRP20050993A2 (en)
IL (1) IL172063A0 (en)
IS (1) IS8136A (en)
MA (1) MA27885A1 (en)
MX (1) MXPA05013960A (en)
NL (1) NL1026438C2 (en)
NZ (1) NZ544046A (en)
PA (1) PA8605301A1 (en)
PE (1) PE20050631A1 (en)
PL (1) PL1638933T3 (en)
PT (1) PT1638933E (en)
SI (1) SI1638933T1 (en)
TW (1) TW200505852A (en)
UY (1) UY28360A1 (en)
WO (1) WO2004110995A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2417727C (en) 2000-07-31 2009-09-01 Nycomed Danmark A/S Fentanyl composition for nasal administration
NZ544046A (en) * 2003-06-17 2009-08-28 Pfizer N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
JP5188807B2 (en) 2004-10-18 2013-04-24 イーライ リリー アンド カンパニー 1- (Hetero) aryl-3-amino-pyrrolidine derivatives for use as mGluR3 receptor antagonists
GB0425766D0 (en) * 2004-11-23 2004-12-22 Pfizer Ltd Novel compounds
US7122683B2 (en) 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
EP1828119A1 (en) * 2004-12-14 2007-09-05 Pfizer Limited N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors
CA2590229A1 (en) * 2004-12-14 2006-06-22 Pfizer Limited N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors
TWI439452B (en) 2005-05-13 2014-06-01 Otsuka Pharma Co Ltd Pyrrolidine compound
AU2006254256B2 (en) 2005-06-02 2012-04-12 F. Hoffmann-La Roche Ag Piperidin-4-yl-amide derivatives and their use as SST receptor subtype 5 antagonists
WO2007135530A2 (en) * 2006-05-22 2007-11-29 Pfizer Limited Pharmaceutically & veterinarily suitable salt
US20080014152A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Intranasal delivery of clenbuterol across the cribriform plate and into the brain
JP5219465B2 (en) * 2006-11-10 2013-06-26 大塚製薬株式会社 Medicine
JPWO2008093737A1 (en) * 2007-01-31 2010-05-20 大日本住友製薬株式会社 Amide derivatives
JP2010189275A (en) * 2007-06-14 2010-09-02 Dainippon Sumitomo Pharma Co Ltd Naphthalene derivative
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
RU2010129690A (en) 2007-12-19 2012-01-27 Дайниппон Сумитомо Фарма Ко., Лтд. (Jp) BICYCLIC HETEROCYCLIC DERIVATIVES
EP2318362B1 (en) 2008-07-24 2013-09-25 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
RU2503662C2 (en) 2008-11-14 2014-01-10 Тереванс, Инк. Crystalline form of 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
US20100267743A1 (en) * 2009-04-15 2010-10-21 Stangeland Eric L 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
AU2010263641A1 (en) 2009-06-24 2012-01-19 Sumitomo Dainippon Pharma Co., Ltd. N-substituted-cyclic amino derivative
RU2535669C2 (en) 2009-07-13 2014-12-20 Тереванс, Инк. 3-phenoxymethyl-pyrrolidine compounds
US8273786B2 (en) 2009-07-21 2012-09-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
US8778949B2 (en) * 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
WO2011119461A1 (en) * 2010-03-22 2011-09-29 Theravance, Inc. 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
CN103153950B (en) 2010-10-11 2015-11-25 施万生物制药研发Ip有限责任公司 serotonin reuptake inhibitors
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE138773C (en)
US3963745A (en) * 1972-04-03 1976-06-15 A. H. Robins Company, Incorporated Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides
US4002757A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated N-(1-substituted-3-pyrrolidinyl)-4-quinolinecarboxamides
US4020072A (en) * 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
GB1574419A (en) * 1977-11-11 1980-09-03 Anphar Sa Piperidine compounds
CH628885A5 (en) * 1978-01-01 1982-03-31 Anphar Sa Piperidine derivative
US5130312A (en) * 1987-07-17 1992-07-14 Janssen Pharmaceutica N.V. Substituted N-(3-hydroxy-4-piperidinyl)benzamides
FR2642069B1 (en) * 1989-01-20 1991-04-12 Rhone Poulenc Sante NOVEL BENZOPYRAN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2000500502A (en) 1995-11-22 2000-01-18 メルク エンド カンパニー インコーポレーテッド Farnesyl-protein transferase inhibitor
WO1999065881A1 (en) 1998-06-19 1999-12-23 Nissan Chemical Industries, Ltd. Heterocyclic compounds as hypoglycemic agents
US6670299B1 (en) * 1999-07-03 2003-12-30 Northwestern University Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts
FR2802206B1 (en) * 1999-12-14 2005-04-22 Sod Conseils Rech Applic 4-AMINOPIPERIDINE DERIVATIVES AND THEIR USE AS MEDICINAL PRODUCTS
DK1311272T3 (en) 2000-03-03 2007-02-26 Eisai R&D Man Co Ltd New methods using cholinesterase inhibitors
DE60125335T2 (en) * 2000-03-06 2007-07-12 Acadia Pharmaceuticals Inc., San Diego AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES
JP2004509891A (en) 2000-09-22 2004-04-02 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Pyrazolopyridine and pyrazolopyridazine as antidiabetic drugs
JP2004509866A (en) 2000-09-25 2004-04-02 アクテリオン　ファマシューティカルズ　リミテッド Substituted amino-aza-cycloalkanes
WO2003024928A2 (en) 2001-09-14 2003-03-27 Novo Nordisk A/S Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
WO2003037865A1 (en) 2001-10-31 2003-05-08 Morphochem Aktiengesellschaft für kombinatorische Chemie Novel anticancer compounds
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
IL165907A0 (en) * 2002-06-24 2006-01-15 Acadia Pharm Inc N-substituted piperidine derivatives as serotonin receptor agents
AU2003249983A1 (en) 2002-07-18 2004-02-09 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
AU2003263393A1 (en) 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
CA2511242C (en) 2002-12-20 2010-01-12 Anita Melikian Inhibitors of human tumor-expressed ccxckr2
NZ544046A (en) * 2003-06-17 2009-08-28 Pfizer N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors

Also Published As

Publication number Publication date
WO2004110995A8 (en) 2005-04-21
AR044715A1 (en) 2005-09-21
IL172063A0 (en) 2009-02-11
JP4137159B2 (en) 2008-08-20
EA200501730A1 (en) 2006-08-25
KR100803796B1 (en) 2008-02-14
AU2004247487B2 (en) 2010-05-20
WO2004110995A1 (en) 2004-12-23
HRP20050993A2 (en) 2006-03-31
CY1110434T1 (en) 2015-04-29
KR20060036927A (en) 2006-05-02
MXPA05013960A (en) 2006-02-24
PL1638933T3 (en) 2008-10-31
UY28360A1 (en) 2005-01-31
SI1638933T1 (en) 2008-10-31
JP2006527758A (en) 2006-12-07
HRP20080339T3 (en) 2008-08-31
MA27885A1 (en) 2006-05-02
EP1638933B1 (en) 2008-06-11
ES2305776T3 (en) 2008-11-01
US20080306123A1 (en) 2008-12-11
DE602004014372D1 (en) 2008-07-24
IS8136A (en) 2005-11-21
AU2004247487A1 (en) 2004-12-23
PE20050631A1 (en) 2005-09-14
BRPI0411594A (en) 2006-08-29
EP1638933A1 (en) 2006-03-29
US7378436B2 (en) 2008-05-27
TW200505852A (en) 2005-02-16
CA2530159C (en) 2010-02-02
NL1026438A1 (en) 2004-12-20
NZ544046A (en) 2009-08-28
ATE398107T1 (en) 2008-07-15
PT1638933E (en) 2008-07-22
EA009881B1 (en) 2008-04-28
DK1638933T3 (en) 2008-07-28
PA8605301A1 (en) 2005-02-04
AP2005003467A0 (en) 2006-12-31
NL1026438C2 (en) 2005-09-20
ECSP056232A (en) 2006-04-19
US20050137229A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
CA2530159A1 (en) N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
FR2809396B1 (en) NOVEL MOLECULES HAVING CALCIMIMETIC ACTIVITY AND THEIR METHOD OF PREPARATION
BR0315047A (en) Compound, pharmaceutical composition comprising the same, process for preparing the pharmaceutical composition, use of the compounds, method of treatment and process for the preparation of the compound
DK496089D0 (en) BIOLOGICALLY ACTIVE PHENYLALKANIC ACID COMPOUNDS AND PROCEDURES FOR PRODUCING THEREOF
SE0104340D0 (en) New compounds
NZ705710A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
CA2476065A1 (en) Inhibitors of histone deacetylase
PT1077930E (en) BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES
RU2002124522A (en) 2-OXO-1-pyrrolidine derivatives, method for their preparation and use
WO2006034833A1 (en) Cyclic diarly ureas suitable as tyrosine kinase inhibitors
SE0104334D0 (en) Therapeutic agents
CA2264556A1 (en) Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
GEP20053459B (en) New Thiadiazoles and Oxidiazoles and Their Use as Phosphodiesterase-7 Inhibitors
FR2800735B1 (en) NOVEL ARALKYL-1,2-DIAMINES HAVING CALCIMIMETIC ACTIVITY AND THEIR METHOD OF PREPARATION
BR0211559A (en) Therapeutically useful compounds, tetracyclic binder compositions and their uses
NO932520D0 (en) PREPARATION FOR HEALING THE DISEASE SJOEGREN'S SYNDROME
RU94046141A (en) Substituted(arylalkoxybenzyl)aminopropaneamide derivatives, processes for preparation thereof, and pharmaceutical composition
KR910004597A (en) 1- (pyridinylamino) -2-pyrrolidinone, preparation method thereof and use thereof as medicament
BR0212676A (en) 5-ht ligand therapeutic compounds, pharmaceutical compositions comprising such compounds and their uses
HU9303082D0 (en) Process for production of 3,4-dihydro-2(1h)-quinolyne-derivatives with neuroprotective action and of pharmaceutical compositions containing them as medical agent
RU2205829C2 (en) Substituted derivative of cyclobutylamine, antibacterial agent and pharmaceutical composition based on thereof
ATE289583T1 (en) STEREOISOMERS OF PROPYL-ISOPROPYLACETAMIDE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME
BR9813607A (en) Compound, process for preparing the same, pharmaceutical composition, and process for treating a disease condition
WO1989001330A3 (en) W-arylsulphonamidoalkanoic acids for treatment of thromboxane mediated diseases
ZA888663B (en) Substituted derivatives of 20,21-dinoreburanamenine,their preparation process and the new intermediates thus obtained,their use as medicaments and the pharmaceutical compositions containing them

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed